Azacitidine

Tier C — Watch / trade

Azacitidine

Celgene Corporation

Originator

2004

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：DNMT1

Brand：Vidaza, Onureg

Indications (approved)：幼年型粒单核细胞白血病, Acute myeloid leukaemia, Myelodysplastic syndrome, Chronic myeloid leukaemia, Chronic myelomonocytic leukaemia

Regional status

Approved

2004-05-19

Approved

2008-12-17

China

Approved

2017-04-24

Japan

Approved

2011-01-21

Factories producing this API4

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

4 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Azacitidine?

Approved indications include: 幼年型粒单核细胞白血病, Acute myeloid leukaemia, Myelodysplastic syndrome, Chronic myeloid leukaemia, Chronic myelomonocytic leukaemia.

When does the Azacitidine patent expire?

No public expiry year is available for Azacitidine yet; this page updates once verified.

How do I get a quote for Azacitidine intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27